A CD19-targeting allogeneic CAR-T using intracellular retention of membrane proteins to prevent TCR expression at the surface was evaluated in a Phase I study (NCT04384393) in patients with NHL [156]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.